Annual report
4360.TEDINET S100R3ZN
Period2022-04-01 → 2023-03-31
Filed2023-06-30
StandardJapan GAAP
ConsolidatedYes
Data checks22 of 22 passed
Key figures · 72
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥10.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥991m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥740m | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥881m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥940m | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥821m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥712m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥821m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥712m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥15.0bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥13.6bn | at 2022-03-31 | Cons. | Assets |
| Total liabilities | ¥4.0bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥3.3bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.8bn | at 2021-03-31d | Cons. | Net assets |
| Cash and deposits | ¥3.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.7bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥714m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥199m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥422m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥125m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥200m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥103.26 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.52 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,384.71 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,300.81 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 73.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.8% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.7% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 236 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 241 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥672m | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥317m | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Operating income | ¥375m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥173m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥760m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥188m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | ¥814m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥242m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥662m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥174m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥11.2bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥10.6bn | at 2022-03-31 | Standalone | Assets |
| Total liabilities | ¥165m | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥79m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥11.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥10.5bn | at 2022-03-31 | Standalone | Net assets |
| Cash and deposits | ¥1.5bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥700m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥83.29 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.05 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥15 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥7.5 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,388.88 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,324.77 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 98.5% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 99.2% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.1% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.7% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 8,625,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 8,625,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Employees | 8 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 7 | at 2022-03-31 | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 60
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥91m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥117m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥6.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥1.1bn |
| Fine Chemical Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥62m |
| Fine Chemical Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥218m |
| Fine Chemical Businessreportable segment | employees | at 2023-03-31 | 96 pure |
| Fine Chemical Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥4.3bn |
| Fine Chemical Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥4.3bn |
| Fine Chemical Businessreportable segment | segment assets | at 2023-03-31 | ¥4.9bn |
| Fine Chemical Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥768m |
| Flame Retardants Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥101m |
| Flame Retardants Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥120m |
| Flame Retardants Businessreportable segment | employees | at 2023-03-31 | 47 pure |
| Flame Retardants Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥6.2bn |
| Flame Retardants Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥6.2bn |
| Flame Retardants Businessreportable segment | segment assets | at 2023-03-31 | ¥3.1bn |
| Flame Retardants Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.3bn |
| Health Support Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥31m |
| Health Support Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥31m |
| Health Support Businessreportable segment | employees | at 2023-03-31 | 14 pure |
| Health Support Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.3bn |
| Health Support Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.3bn |
| Health Support Businessreportable segment | segment assets | at 2023-03-31 | ¥845m |
| Health Support Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥31m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥195m |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥369m |
| —segment total | employees | at 2023-03-31 | 157 pure |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥11.9bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥11.9bn |
| —segment total | segment assets | at 2023-03-31 | ¥8.9bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥70m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥107m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥4.9bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥1.0bn |
| Fine Chemical Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥316m |
| Fine Chemical Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥200m |
| Fine Chemical Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥4.5bn |
| Fine Chemical Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥4.5bn |
| Fine Chemical Businessreportable segment | segment assets | at 2022-03-31 | ¥5.0bn |
| Fine Chemical Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥637m |
| Flame Retardants Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥196m |
| Flame Retardants Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥113m |
| Flame Retardants Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥5.0bn |
| Flame Retardants Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥5.0bn |
| Flame Retardants Businessreportable segment | segment assets | at 2022-03-31 | ¥2.9bn |
| Flame Retardants Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥993m |
| Health Support Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥80m |
| Health Support Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥29m |
| Health Support Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| Health Support Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| Health Support Businessreportable segment | segment assets | at 2022-03-31 | ¥773m |
| Health Support Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥158m |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥593m |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥343m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥10.7bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥10.7bn |
| —segment total | segment assets | at 2022-03-31 | ¥8.6bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥1.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,263
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of employees | CurrentYearInstant | 236 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 8 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 41.5 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 10.2 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 7324950 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 8 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 8 | |
| Research and development expenses research and development activities | CurrentYearDuration | 340000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36769-000FineChemicalBusinessReportableSegmentsMember | 209000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36769-000FlameRetardantsBusinessReportableSegmentsMember | 118000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36769-000HealthSupportBusinessReportableSegmentsMember | 13000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 287000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36769-000FineChemicalBusinessReportableSegmentsMember | 62000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36769-000FlameRetardantsBusinessReportableSegmentsMember | 101000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36769-000HealthSupportBusinessReportableSegmentsMember | 31000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 8625000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 8625000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 8625000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 8625000 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 7 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 18 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 81 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 16 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 6 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 2671 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 2799 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 6234 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 2382 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 38119 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 1782 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 82 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 37467 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 86066 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 18400 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.0724 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0277 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.4429 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.0207 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0010 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.4353 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 1608000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.2017 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 1340000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.1681 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 324000 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0407 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 22 of 22 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |